 Hookipa Pharma Inc NASDAQ: HOOK has entered into a clinical collaboration and supply agreement with Merck Co Inc NYSE: MRK. The collaboration will evaluate the combination of HB-200 and Keytruda pembrolizumab as first-line treatment of advanced head and neck squamous cell carcinoma HNSCC. 